Scalper1 News
Specialty-drug giant and IBD 50 stock Actavis beat Wall Street’s first-quarter estimates Monday and for the first time offered 2015 earnings guidance that included newly acquired Allergan. Highly rated Ligand Pharmaceuticals (LGND) and Endo International (ENDP) also topped EPS targets. Actavis’ (ACT) earnings rose 23% vs. a year earlier to $4.30 a share, 37 cents above analysts’ consensus, according to Thomson Reuters. Sales jumped Scalper1 News
Scalper1 News